Q3 Asset Management Sells 662 Shares of SPDR S&P Biotech ETF (XBI)

Q3 Asset Management lessened its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 61,243 shares of the exchange traded fund’s stock after selling 662 shares during the period. SPDR S&P Biotech ETF accounts for about 6.4% of Q3 Asset Management’s investment portfolio, making the stock its 5th biggest holding. Q3 Asset Management’s holdings in SPDR S&P Biotech ETF were worth $5,829,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in shares of SPDR S&P Biotech ETF by 64.5% in the first quarter. JPMorgan Chase & Co. now owns 1,462,600 shares of the exchange traded fund’s stock valued at $128,314,000 after acquiring an additional 573,431 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of SPDR S&P Biotech ETF in the first quarter valued at about $118,628,000. Assetmark Inc. lifted its position in shares of SPDR S&P Biotech ETF by 271,147.4% in the second quarter. Assetmark Inc. now owns 1,264,013 shares of the exchange traded fund’s stock valued at $120,321,000 after acquiring an additional 1,263,547 shares in the last quarter. CI Investments Inc. purchased a new position in shares of SPDR S&P Biotech ETF in the first quarter valued at about $52,366,000. Finally, First Republic Investment Management Inc. lifted its position in shares of SPDR S&P Biotech ETF by 0.5% in the first quarter. First Republic Investment Management Inc. now owns 439,407 shares of the exchange traded fund’s stock valued at $38,550,000 after acquiring an additional 2,143 shares in the last quarter.

Shares of SPDR S&P Biotech ETF stock opened at $94.95 on Friday. SPDR S&P Biotech ETF has a 52 week low of $74.35 and a 52 week high of $101.55.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply